Novartis raised its full-year core operating-income outlook after third-quarter sales grew 4% to US$14.522 billion. But reported net income fell 70% to US$1.196 billion. Its 27 October results show why a stronger adjusted measure cannot be read as an increase in reported profit.
An impairment widens the earnings gap
Reported operating income fell 59% to US$1.843 billion. Novartis cited higher research-and-development expenses, including a US$1.9 billion partial impairment of the del-desiran asset, and higher other expense. An impairment reduces an asset’s accounting value; it is not a fall in the current quarter’s sales of the same amount.
Core operating income increased 11% to US$6.036 billion, while core net income rose 8% to US$4.655 billion. These growth rates are in US dollars. Novartis’s core measures remove specified items, including intangible-asset amortisation and impairment charges. They are non-IFRS measures and must be read alongside—not instead of—the reported accounts.
The outlook is for core income, not all profit measures
For 2026, the company now expects core operating income to be flat to grow at a low-single-digit rate, replacing its previous expectation of a low-single-digit decline. This outlook is in constant currencies, meaning it removes estimated exchange-rate effects, and is subject to unforeseen events. It does not forecast equivalent growth in reported net income.
Novartis kept its low-single-digit sales-growth outlook. Readers should watch whether sales growth continues to offset generic competition and how further asset charges affect the gap between reported and core earnings. No analyst-consensus comparison or share-price move has been verified for this report.
| Measure | Disclosed figure | Basis or condition | Primary evidence |
|---|---|---|---|
| Q3 net sales | US$14.522bn; +4% | Reported US-dollar growth; also +4% in constant currencies | Novartis release, p1 |
| Q3 reported net income | US$1.196bn; −70% | IFRS Accounting Standards result; US-dollar comparison | Novartis release, p1 |
| Q3 core net income | US$4.655bn; +8% | Non-IFRS measure; US-dollar comparison | Novartis report, pp3,45 |
| Q3 operating income | US$1.843bn reported; US$6.036bn core | Reported −59%; core +11% in US dollars | Novartis release, pp1–2 |
| del-desiran impairment | US$1.9bn partial charge | Write-down of an acquired in-process R&D asset; included in reported results | Novartis release, p2 |
| 2026 core operating-income outlook | Flat to low-single-digit growth | Raised from low-single-digit decline; constant-currency forecast, barring unforeseen events | Novartis release, p7 |
Sources: Novartis Q3 2026 release, pages 1–2 and 7, captured at 2026-10-27T10:55:24.423Z; and its Condensed Interim Financial Report, key figures and non-IFRS definitions on pages 3 and 45, captured at 2026-10-27T10:55:26.880Z. Results cover the quarter ended 30 September 2026. Exact PDF files are retained locally.
AI-assisted reporting checked against the linked official documents; not independent human editorial approval. Publisher-designated author: Tatai. Information only, not investment advice.
Recorded source observation: . This is a source-check timestamp, not a market quote or a new article update.